Multicenter prospective clinical trial with low dose Gentuzumab-Ozogamicin plus fludarabine, Cytarabine, Idarubicin, (GO.FLAI) as induction therapy of CD33-positiveacute myeloid leukemia AML patients younger than 65 years

CANDONI A

MARTINELLI G

GHERLIZONI F

DAMIANI, Daniela